Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
Press releases
-
AlzeCure’s Alzheimer’s project receives approval to start next clinical phase I study with ACD856
August 30, 2021
-
AlzeCure’s ACD856 demonstrates good tolerability in Phase I clinical trial and is approved for additional doses
August 27, 2021
-
AlzeCure publishes its interim report for January – June 2021
August 25, 2021